NZ597000A - Compositions and methods for administration of vaccines against dengue virus - Google Patents

Compositions and methods for administration of vaccines against dengue virus

Info

Publication number
NZ597000A
NZ597000A NZ597000A NZ59700010A NZ597000A NZ 597000 A NZ597000 A NZ 597000A NZ 597000 A NZ597000 A NZ 597000A NZ 59700010 A NZ59700010 A NZ 59700010A NZ 597000 A NZ597000 A NZ 597000A
Authority
NZ
New Zealand
Prior art keywords
dengue
composition
serotypes
dengue virus
attenuated
Prior art date
Application number
NZ597000A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jorge E Osorio
Charalambos D Partidos
Joseph N Brewoo
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ597000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Priority to NZ618158A priority Critical patent/NZ618158A/en
Publication of NZ597000A publication Critical patent/NZ597000A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ597000A 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus NZ597000A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ618158A NZ618158A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01
PCT/US2010/036726 WO2010141386A1 (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Publications (1)

Publication Number Publication Date
NZ597000A true NZ597000A (en) 2014-07-25

Family

ID=43220488

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ597000A NZ597000A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus
NZ618158A NZ618158A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ618158A NZ618158A (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Country Status (17)

Country Link
US (2) US9211323B2 (https=)
EP (1) EP2438198A4 (https=)
JP (2) JP5848243B2 (https=)
KR (1) KR101876304B1 (https=)
CN (2) CN102449172A (https=)
AU (3) AU2010256845B2 (https=)
CA (1) CA2763944A1 (https=)
CL (1) CL2011003043A1 (https=)
CO (1) CO6470882A2 (https=)
CU (1) CU20110219A7 (https=)
IL (2) IL216706A0 (https=)
MX (1) MX343172B (https=)
MY (1) MY184428A (https=)
NZ (2) NZ597000A (https=)
PH (1) PH12016502431A1 (https=)
SG (1) SG176299A1 (https=)
WO (1) WO2010141386A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US11007261B2 (en) 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231570T2 (de) * 1991-09-19 2001-06-21 Us Of America Represented By D Chimäre und/oder wachstumgehemmte Flaviviren
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
US20080193477A1 (en) 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
DK2589602T3 (en) * 2006-08-15 2016-07-25 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of dengue virus vaccine components
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus

Also Published As

Publication number Publication date
AU2016277660A1 (en) 2017-01-12
CL2011003043A1 (es) 2012-07-20
US10010600B2 (en) 2018-07-03
CN102449172A (zh) 2012-05-09
MY184428A (en) 2021-04-01
CA2763944A1 (en) 2010-12-09
KR101876304B1 (ko) 2018-07-10
JP5848243B2 (ja) 2016-01-27
JP2012528794A (ja) 2012-11-15
JP2016033151A (ja) 2016-03-10
WO2010141386A1 (en) 2010-12-09
IL216706A0 (en) 2012-02-29
PH12016502431A1 (en) 2019-02-11
CN107913406A (zh) 2018-04-17
KR20120027396A (ko) 2012-03-21
AU2010256845B2 (en) 2016-09-22
US20100303860A1 (en) 2010-12-02
US20160129102A1 (en) 2016-05-12
NZ618158A (en) 2015-05-29
CU20110219A7 (es) 2012-06-21
US9211323B2 (en) 2015-12-15
AU2010256845A1 (en) 2011-12-22
MX343172B (es) 2016-10-26
EP2438198A4 (en) 2014-05-14
MX2011012807A (es) 2012-01-30
AU2019200212A1 (en) 2019-01-31
CO6470882A2 (es) 2012-06-29
EP2438198A1 (en) 2012-04-11
IL243204A0 (en) 2016-02-29
SG176299A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
MX2009006178A (es) Vacuna contra salmonela.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
TW200722101A (en) Novel composition
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MY169275A (en) Method of immunization against the four serotypes of dengue
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
AR055603A1 (es) Vacuna contra la infeccion por virus del dengue
JP2012528794A5 (https=)
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
WO2013104995A3 (en) Compositions and methods for treating viral infections
NZ578662A (en) Immediate protection against pathogens via vaccination with replication incompetent mva (modified vaccinia virus ankara)
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
NO20090290L (no) Polyvalent vaksine mot salmonid alfavirusinfeksjoner

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: INVIRAGEN, INC., US

Free format text: OLD OWNER(S): INVIRAGEN, INC.; DAN T STINCHCOMB; JORGE E OSORIO; CHARALAMBOS D PARTIDOS; JOSEPH N BREWOO

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

ASS Change of ownership

Owner name: TAKEDA VACCINES, INC., US

Effective date: 20140619

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAY 2017 BY AJ PARK

Effective date: 20150115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2018 BY CPA GLOBAL

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAY 2019 BY CPA GLOBAL

Effective date: 20180412

LAPS Patent lapsed